Double-blind Placebo Controlled, Randomized, Parallel-group, Phase II study in subjects with relapsing forms of Muiltiple Sclerosis to evaluate the effects of two doses of CDP323 over 24 weeks with a rater blind MRI follow up over 12 weeks